Abstract
Purpose :
Evaluating the efficacy of Vyzulta as replacement therapy for latanoprost in primary open angle glaucoma (POAG) patients within a large tertiary care center.
Methods :
A retrospective review of patients with POAG, who were treated with Vyzulta as replacement therapy (RT) for latanoprost, was performed from January 1st, 2018 to June 30th, 2021. Noted demographic and clinical data include age, race, gender, systemic diabetes mellitus (DM) or hypertension (HTN), intraocular pressure (IOP), and medical/surgical management. Data was collected prior to the addition of Vyzulta to patients' drop regimen (treated baseline) as well as at 1, 3, 6, and 12 months follow-up from initial Vyzulta start date. Criteria for success of Vyzulta as RT for latanoprost was defined as a percentage reduction of IOP from treated baseline, resulting in IOP between 5 - 21 mmHg at two consecutive follow-up visits, without additional medical or surgical intervention needed within 12 months. Percentages analyzed included 10%, 15%, 20%, and 30% IOP drop from treated baseline, and were defined as loose (LCr), qualified (QCr), moderate (MCr) and stringent (SCr) success criteria, respectively. QCr was chosen as 15% reduction of IOP from treated baseline as 80% of patients had IOP < 24 mmHg; thus success by QCr statistically would best correlate with a clinically meaningful decrease of IOP to within a normal range.
Results :
2611 patient charts reviewed; 65 patients (65 eyes) met inclusion criteria and were analyzed. Mean age (SD) was 72.28 (11.84) years. Demographics included 50.8% male, 84.6% African American, 33.8% with DM, and 75.4% with HTN. Mean baseline IOP (SD) was 22.2 (6.07) mmHg. Success rate of Vyzulta as RT for latanoprost was 40%, 29.2%, 18.5%, and 10.8% based on LCr, QCr, MCr, and SCr, respectively. There is no significant difference in success with any criteria, among patients with or without DM or HTN (p>0.05).
Conclusions :
In an urban patient population with POAG, Vyzulta as RT for latanoprost is successful in 29% of patients in which goal IOP for treatment is IOP at 15% reduction from treated baseline, resulting in IOP between 5 - 21 mmHg at two consecutive follow-up visits, without additional medical or surgical intervention needed within 12 months.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.